Literature DB >> 9843216

Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.

A Puel1, S F Ziegler, R H Buckley, W J Leonard.   

Abstract

Severe combined immunodeficiency (SCID) is caused by multiple genetic defects. The most common form of SCID, X-linked SCID (XSCID), results from mutations in IL2RG (ref. 4), which encodes the common cytokine receptor gamma chain (gamma(c)) that is shared by the IL-2, IL-4, IL-7, IL-9 and IL-15 receptors. In XSCID and SCID resulting from mutations in JAK3, which encodes a Janus family tyrosine kinase that couples to gamma(c) and is required for gamma(c)-dependent signalling, T- and natural killer (NK)-cells are decreased but B-cell numbers are normal (T(-)B(+)NK(-)SCID). Some SCID patients lack T cells but retain NK cells. Given diminished T-cell development in Il7- or Il7r-deficient mice and that Il/7r-deficient mice have NK cells, we hypothesized that T(-)B(+)NK(+) SCID might result from defective IL-7 signalling, although apparent differences in the role of the IL-7/IL-7R pathway in humans and mice in T-cell and B-cell development have been suggested. We now demonstrate that defective IL7R expression causes T(-)B(+)NK(+) SCID, indicating that the T-cell, but not the NK-cell, defect in XSCID results from inactivation of IL-7Ralpha signalling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9843216     DOI: 10.1038/3877

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  253 in total

Review 1.  Primary T-lymphocyte immunodeficiencies.

Authors:  A Fischer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

Review 2.  Interleukin-2 signaling and inherited immunodeficiency.

Authors:  N A Cacalano; J A Johnston
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 3.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 4.  Jaks and stats as therapeutic targets.

Authors:  J J O'Shea; R Visconti; T P Cheng; M Gadina
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 6.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 7.  Interlinking interleukin-7.

Authors:  Christina Kittipatarin; Annette R Khaled
Journal:  Cytokine       Date:  2007-09-04       Impact factor: 3.861

8.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

Review 9.  TSLP in epithelial cell and dendritic cell cross talk.

Authors:  Yong-Jun Liu
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

10.  Human lymphoid development in the absence of common γ-chain receptor signaling.

Authors:  Lisa A Kohn; Christopher S Seet; Jessica Scholes; Felicia Codrea; Rebecca Chan; Sania Zaidi-Merchant; Yuhua Zhu; Satiro De Oliveira; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Donald B Kohn; Gay M Crooks
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.